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Abstract
Background Intralesional 5-fluorouracil (5-FU) in combination with triamcinolone acetonide (TAC) has been recom-
mended as a promising alternative for keloids not responding to silicone-based products, cryotherapy or intralesional
corticosteroids alone. Although numerous studies support the efficacy of this regime, there is a lack of objective data.
Objectives In this study, we evaluate the therapeutic effect of four courses of intralesional 5-FU in combination with
TAC (3 : 1) utilizing 3D analysis (PRIMOSpico), ultrasound and scar scales such as the Patient and Observer Scar
Assessment Scales (POSAS) and the Dermatology Life Quality Index (DLQI).
Methods Twenty-five patients with keloids were treated using 5-FU and TAC every 4 weeks. Objective assessments
were performed and the scar scales administered at baseline, as well as during consecutive visits at 1- and 12-month
follow-up (FU). Routine laboratory tests were performed at baseline and at 1-month FU.
Results 3D PRIMOS and ultrasound measurements revealed highly significant and stable reductions in height (baseline
mean score: 4.0  1.7 mm, 1-month FU mean score: 1.5  0.8 mm, 12-month FU mean score: 1.8  0.9 mm,
P = <0.0001), volume (baseline mean score: 1,105  911.5 mm3, 1-month FU mean score: 416.1  218.1 mm3, 12-
month FU mean sore: 431.2  253.6 mm3, P = <0.0001, respectively) and penetration depth of keloids (relative reduc-
tion between baseline and 12-month FU of 74.4%, P = <0.0001). The POSAS and DLQI scales confirmed significant
objective and subjective improvements in scar appearance in all categories. The life quality associated with keloid
appearance improved from a ‘moderate effect’ to a ‘small effect’ throughout the course of the study.
Conclusions Results of this study confirm the efficacy and safety of the combination of 5-FU and TAC in keloids.
Treatments were well tolerated and demonstrated stable results at 12-month FU.
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The extent of scarring following surgery or trauma is difficult to
predict and both physicians and patients are highly concerned
with minimizing scar appearance and related symptoms. Even
small ameliorations in scarring are clinically meaningful. Espe-
cially keloids pose a significant challenge for treating physicians.
A number of treatment regimens have been developed, such as
the application of silicone-based products, cryotherapy or
intralesional corticosteroids. Keloids may affect large parts of the
skin surface and lead to severe functional impairment, particu-
larly in genetically prone patients. Successful treatment using
conventional means has proven difficult, with low rates of sus-
tained responses and high relapse rates.
The commonly used glucocorticosteroid triamcinolone ace-
tonide has many effects, including an anti-mitotic property
inhibiting keratinocytes and fibroblasts and the suppression of
tissue inflammation and vasoconstriction, resulting in keloid
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regression.1,2 Whereas, 5-fluorouracil (5-FU) inhibits the prolif-
eration of fibroblasts as a pyrimidine analogue3 and has been
successfully used for the treatment of keloids for many years.4,5
Most studies have focused on demonstrating the effects of
high-dose 5-FU therapy (40–50 mg/mL), while others have pro-
moted a ‘low-dose’ therapy using 1.4–3.5 mg/mL of 5-FU.6,7
More recently, a growing number of studies have supported the
combination of intralesional 5-FU and crystalline triamcinolone
acetonide (TAC) in a ratio of either 9 : 1 or 3 : 1. Combinations
appear to be superior to monotherapy with TAC.8-11
Based on the relevant literature, combinations of 5-FU and
TAC may thus be considered for the treatment of keloids and
seem to lack any systemic side effects. However, data on such
combinations based on objective measurements are widely
missing. In the majority of studies, follow-up (FU) periods have
remained relatively short.
Materials and Methods
Patients and study methodology
Upon ethical approval of the proposed research, 25 patients, six
females and 19 males were enrolled in the clinical study.
Prospective patients had to be of legal age without any malignant
illnesses. Patients enrolled were previously treated with cryother-
apy (spray cryotherapy using liquid nitrogen twice for 10 s;
cryotherapy was usually performed 15–30 min before the injec-
tion of TAC, since success rates appear to be increased based on
the larger amount of TAC that can be injected into the scar due
Table 1 Patient characteristics
Patient Age (years) Skin type Localization Number Existance
(years)
Development Previous therapy Family
history
1 28 IV Shoulder 5 8 Spontaneous Cryotherapy, TAC None
2 30 II Chest, shoulder 8 11 Spontaneous Cryotherapy, TAC,
laser therapy
None
3 26 II Chest 4 8 Acne Cryotherapy, TAC,
silicone gel sheeting
Sister
4 38 IV Chest, back, shoulder >10 >20 Spontaneous Cryotherapy, TAC None
5 22 II Chest, shoulder >10 3 Spontaneous Cryotherapy, TAC None
6 21 III Chest, back, shoulder >10 4.5 Acne Cryotherapy, TAC None
7 30 II Chest 5 6 Injury Cryotherapy, TAC None
8 27 II Chest 1 2 Surgery Cryotherapy, TAC None
9 25 III Back, shoulder 3 9 Spontaneous Cryotherapy, TAC Cousin
10 25 II Shoulder >10 6 Spontaneous Cryotherapy, TAC None
11 19 IV Shoulder 4 3 Surgery Cryotherapy, TAC None
12 22 II Chest 3 2 Acne Cryotherapy, TAC None





14 25 II Arms 2 5 Injury Cryotherapy, TAC None
15 37 IV Chest 2 12 Surgery Cryotherapy, TAC Daughter
16 49 II Chest 1 >20 Surgery Cryotherapy, TAC,
surgery
None
17 21 II Chest, back, shoulder >10 4 Acne Cryotherapy, TAC None
18 27 IV Chest, shoulder, arms 6 6 Acne Cryotherapy, TAC,
surgery
Sister




20 28 II Chest, shoulder 7 10 Acne Cryotherapy, TAC None
21 24 II Chest, shoulder >10 8 Acne Cryotherapy, TAC None
22 19 II Back, shoulder >10 3 Acne Cryotherapy, TAC None




24 48 II Chest, shoulder 7 >30 Spontaneous Cryotherapy, TAC None
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to oedema formation caused by cryotherapy) and TAC every
4 weeks at least three times without significant improvement. In
order to ensure the comparability of the results of individual
patients, keloids had to have persisted for at least two years.
Infectious or immunosuppressive diseases, as well as Brivudine
intake up to 4 weeks prior to the study, were considered exclu-
sion criteria. Written informed consent was obtained from each
patient.
Routine blood tests with complete blood count, excluding
pancytopenia, basic metabolic panel, cholesterol and lipids, thy-
roid, liver and kidney function and pregnancy tests in females
were performed prior to the first treatment session and at 1-
month FU.
The mean age of the study cohort was 28.8  9.3 years, with
Fitzpatrick skin types ranging from I–IV. Patients showed an
average keloid number of 6.3  3.4 per person, with a mean scar
age of 8.6  6.7 years. Keloids mostly presented on patients’
chests, shoulders and backs and predominantly developed as a
result of acne. In some patients, keloids resulted from surgery or
occurred spontaneously without any memorable trauma. In six
patients, a positive family history of keloids was recorded
(Table 1).
A total of 50 keloids were treated in the patient population.
Keloids inflicting a high level of patient distress in terms of pain
or aesthetic impairment were chosen. Prior to each treatment, as
well as at 1- and 12-month FU, data were collected using digital
photography, the three-dimensional Phase shift rapid in vivo
measurement of skin (PRIMOSpico) software, ultrasound and
standardized questionnaires (POSAS, DLQI) (Fig. 1).
5-fluorouracil and triamcinolone acetonide
Every patient received four intralesional injections of a combina-
tion of 5-FU (50 mg/mL) and a crystalline TAC suspension
(40 mg/mL) at a ratio of 3 : 1 until a blanching effect occurred.
Injections were administered at monthly intervals. Due to an
objection to a negative control by the ethics committee of the
Patient with a keloid
Resistant to treatment after 3x cryotherapy + TAC
Inclusion criteria
• ≥ 18 years old patient
• skin type I-IV Fitzpatrick
• ≥ 2 years of keloid’s persistence    
Exclusion criteria
• Pregnancy
• Infectious or immunosuppressive disease
• Anemia, leukopenia, thrombocytopenia
• Depression of bone marrow
• Participation in any other study 





Assessment prior to each treatment
digital photography, PRIMOS 3D, ultrasound, 
POSAS, DLQI
4 treatments at intervals of 4 weeks
5-FU 50 mg/ml + TAC 40 mg/ml (3 : 1 ratio)
1 month / 12 months FU assessment
pregnancy and blood test*, digital photography, 
PRIMOS 3D, ultrasound, POSAS, DLQI
Drop out 
• systemic side effects
• intolerable local side
Figure 1 Study algorithm: Every patient with a keloid received four treatments 5-FU/TAC after study inclusion. Data were collected at
baseline, prior to each treatment and at one-month and 12-month FU, respectively. (5-FU, 5-Fluorouracil; DLQI, Dermatology Life Quality
Index; FU, follow-up; POSAS, Patient and observer scar assessment scale; PRIMOS, phase shift rapid in vivo measurement of skin; TAC,
triamcinolone acetonide; *Performed at 1-month FU).
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 2436–2444
2438 Reinholz et al.
Ludwig Maximilian University, no negative control was allowed.
Standardized injection techniques were employed using the same
syringe size (5 mL), needle size (27 Gauge), Luer Lock and
brands of pharmaceutical drugs. Injection volume depended on
the size of each patient’s keloids. The average injected suspen-
sion volumes per keloid were as follows: visit 1: 1 mL, visit 2:
0.8 mL, visit 3: 0.6 mL and visit 4: 0.4 mL.
Digital photography
Professional photographers documented clinical changes in
keloids over the course of the study using a Nikon D5 with an
AF-S Micro Nikkor 60 mm lens. Written informed consent was
obtained prior to each photograph.
Three-dimensional imaging device: phase shift rapid
in vivo measurement of skin (PRIMOSpico)
A total of 50 keloids were objectively measured using PRI-
MOSpico, a three-dimensional, high-resolution, non-invasive
clinical imaging device (Lite Device, GF Messtechnik GmbH,
Teltow, Germany). PRIMOSpico has been successfully used to
analyse different kinds of pathologic scarring, such as
hypertrophic burn scars,12 self-harm scars13 and striae distensae
albae,14 and has become a standard for scar imaging.
Ultrasound
A high-resolution B-mode-image sonogram was used for non-
invasive analysis of the cutaneous penetration and elevation of
keloids. A total of 25 keloids were measured utilizing an 11-
MHz transducer (Logiq; P6 Pro; GE Healthcare, Solingen, Ger-
many). One representative keloid was selected per patient.
Assessment scales
To analyse patient quality of life throughout the study, the DLQI
was employed. To assess both patients and observers’ subjective
opinions concerning the severity of scarring, we evaluated the
keloids throughout the study using the well-established POSAS.15,16
Data analysis
The GraphPad Prism software (GraphPad software Inc., La Jolla,
CA, USA) was used for statistical analysis and visualization of
results. P-values of *P = <0.05 were considered statistically sig-
nificant. Data were analysed for Gaussian distribution by the
application of D’Agostino and Pearson omnibus normality test.
For non-parametric data, the Wilcoxon matched-pairs signed-
rank test was used to individually compare changes between
baseline and FU visits. The paired t-test was applied to such data
without Gaussian distribution.








































Figure 2 Absolute height (a) and absolute volume of keloids (b)
using PRIMOS for objective analysis. (n = 50, ****P = <0.0001,
ns = non-significant, V = visit, FU = follow-up).
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Figure 3 Relative height (a) and relative volume of keloids (b)
throughout the study. (n = 50, V = visit, FU = follow-up).
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Results
PRIMOSpico
Objective evaluation of 50 keloids using PRIMOSpico made it
possible to accurately calculate the height (mm) and volume
(mm3) of pathologic scars in absolute and relative values.
Throughout the study, both keloid height (Smax) and volume
decreased significantly. Keloid height and volume were reduced
by 59.3% and 53.1%, respectively, between baseline and 12-
month FU. Both values decreased continuously after every treat-
ment session up until 1-month FU, from which point no further
progress was observed (Figs 2–4). These results remained stable
Figure 4 21-year-old male patient suffering from keloids on the chest, back and shoulder persisting for 4.5 years as a consequence to
severe acne. PRIMOS data shows baseline, visit 2–4 and 1-month FU, respectively, left to right (a). Baseline (left) and 1-month FU (right)
comparison in the colour image filter (b).
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until the 12-month FU for most of the variables measured, with
exception of the scar height measured by PRIMOSpico, which
revealed a minimal increase between 1- and 12-month FU
(1.5  0.8 mm vs. 1.8  0.9 mm, respectively).
Ultrasound
Ultrasound examinations of 25 keloids showed steady decreases
in both skin expansion and penetration depth throughout the
study. (Fig. 5) Overall, a reduction in skin expansion by 65.2%
was observed between the baseline and the 12-month FU mea-
surement. Penetration depth also showed significant improve-
ment, decreasing by 74.4% between baseline and 12-month FU
(Fig. 6).
Assessment
Patient and Observer Scar Assessment Scales (POSAS) All
parameters in the patient score revealed significant positive
changes after treatment. Pruritus and pain were dramatically
reduced by 57% and 55%, respectively. Scar thickness and stiff-
ness also showed drastic improvements, scoring 43% and 42%
lower at 12-month FU when compared to baseline (P < 0.0001
for all measurements). The patients’ overall opinion of the scars
improved by 39% throughout the study (P < 0.0001) (Fig. 7).
The observer data revealed statistically significant changes in
all examined scar parameters. Scar pliability enhanced by 54%
throughout the study. Other scar characteristics such as pigmen-
tation, relief and thickness presented with reduced scores by
46%, 45% and 44%, respectively, (P < 0.0001 for all measure-
ments). The observer’s overall opinion of the examined scars
improved by 52% between the baseline measurements and 12-
month FU (P < 0.0001) (Fig. 7).
Dermatology Life Quality Index (DLQI) Prior to treatment,
keloids had a moderate effect on the quality of life of affected
patients (baseline mean score: 8.3  4.8 points). At 1- and 12-
month FU, the pathologic scars only had a small effect (1 month
FU mean score: 2.6  2.2 points, 12-month FU mean score:
2.6  2.4), thus producing a significant and stable reduction in
Figure 5 B-mode-ultrasound with measurements of absolute elevation and cutaneous penetration of keloid at baseline (a), at 1-month
FU (b) and at 12-month FU (c).
(a)
(b)

































Figure 6 The absolute elevation of keloids (a) as well as the abso-
lute penetration depth of keloids (b) was measured using B-mode
ultrasound. (n = 25, ****P = <0.0001, ns = non-significant,
V = visit, FU = follow-up).
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the scar-associated impairment of the patients’ quality of life
(Fig. 8).
Adverse side effects All 25 patients completed the study. The
treatment of keloids with 5-FU and TAC was very well tolerated
and regular laboratory tests did not reveal any evidence of sys-
temic side effects.
The most common local side effects were hyperpigmentation
(n = 9) and telangiectasia of keloids (n = 6), lasting over the
course of the study. Furthermore, ulcerations were seen in five
cases, healing without sequelae. Some patients showed both
hyperpigmentation and ulceration (n = 3) (Table 2).
All patients were strictly instructed not to scratch the ulcera-
tions and, in case of doubt, to use a light body lotion and to alle-
viate itching and avoid inducing further keloid formation due to
scratching artefacts.
Discussion
Treatment of excessive scarring, in particular keloids, remains
difficult. Even though a significant number of patients benefit
from conventional therapeutic approaches such as cryotherapy
and intralesional corticosteroids,17 there are still a significant
number of keloids that appear not responding to these
approaches or that reoccur after initially successful treatments.18
5-FU has been utilized for the treatment of keloids for many
years.4 While TAC only suppresses cell proliferation, 5-FU
induces apoptosis and may thus lead to superior and sustained
results.19 Intralesional injections of 5-FU for the treatment of
keloids have been relatively well studied and have demonstrated
good efficacy in 18 randomized control trials, prospective clini-
cal trials and case series.
5-FU Monotherapy has been shown to deliver good results
when treating keloids. Recently, LaRanger and colleagues anal-
ysed the efficacy of 5-FU as an adjunct after the excision of sev-
ere keloids. After weekly to bi-weekly injections for a total of
four sessions beginning 2 weeks after keloid excision, this group
documented no recurrence over a follow-up time frame of
2 years.20 Hietanen et al. compared the efficacy of TAC (20 mg/
mL) and 5-FU (50 mg/mL) when treating a total of 50 keloids in
their randomized trial. During their follow-up, they documented
a similar efficacy for both measures but noted a significantly
lower rate of side effects for 5-FU treatment.21
In particular, the combination of 5-FU and TAC appears
more effective than 5-FU or TAC alone.8,9,11,22,23
The ratios of 5-FU and TAC used in different publications
vary, although ratios of 1 : 9 or 1 : 3 are most commonly used.















Figure 8 The Dermatology Life Quality Index (DLQI) shows the
impact of keloids on patients’ quality of life comparing baseline
(V1) to 1- and 12-month FU; 0–1 points = no effect on patients’ life
quality; 2–5 points = small effect; 6–10 points = moderate effect;
11–20 points = very large effect; 21–20 points = extremely large























































































Figure 7 (a) Patient scar assessment scale rating characteristics
of keloids comparing baseline to 12 months follow-up. (b) Obser-
ver scar assessment scale using characteristics of keloids compar-
ing baseline to 12 months follow-up. (n = 25, ****P = <0.0001).
Table 2 Adverse side effects resulting from treatments





Hyperpigmentation (resolved with sequelae) 9 36%
Teleangiectasia (resolved with sequelae) 6 24%
Ulceration (resolved without sequelae) 5 20%
Ulceration, hyperpigmentation
(hyperpigmentation resolved with sequelae)
3 12%
Systemic side effects None 0
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020, 34, 2436–2444
2442 Reinholz et al.
Protocols also show significant variation with regard to the
intervals between sessions, ranging from once weekly to every
4 weeks. However, most of these studies rely on rather subjective
scales and few objective measurements; in addition, relatively
few studies have used long-term FU periods. While all studies
show that the combination of TAC and 5-FU has certain bene-
fits, based on discussions among experts in the field of scar man-
agement, it becomes apparent that the injection of a 3 : 1 ratio
of 5-FU to TAC is becoming the most common procedure (M.
Reinholz, A. G€urtler, H. Schwaiger, J. P€otschke, & G.G. Gauglitz,
unpublished data). However, two recently published studies
have demonstrated the efficacy both using the 1 : 9 ratio com-
paring the combination of 5-FU/TAC compared with TAC alone
or the application of either TAC and 5-FU alone, respec-
tively.11,24
While Srivastava et al. largely relied on the Vancouver Scar
Scale, Khalid et al. utilized the POSAS to evaluate their results.
Here, we utilized measuring techniques such as PRIMOSpico
and ultrasound to objectively prove changes in scar volume,
penetration depth and height to validate the efficacy of injecting
a 3 : 1 ratio of 5-FU (50 mg/mL) and a crystalline TAC suspen-
sion (40 mg/mL) directly into keloid tissue every 4 weeks. The
injected volume was limited to 4 mL per injection per patient,
this corresponds to a maximum dose of 150 mg 5-FU and
40 mg TAC per injection per patient. Using this approach, the
dosage used is below the chemotherapeutic dose of 200–600 mg/
m2, depending on the indication. Following current guidelines
for pathologic scarring,1,25 we only included patients who had
undergone previous therapeutic approaches which did not exhi-
bit lasting improvements after at least three attempts. In order to
ensure the comparability of the results of individual patients,
keloids had to have persisted for at least 2 years.
Among our study population of 25 patients, we were able to
demonstrate that keloid volume, height and penetration depth
significantly decreased after four treatment sessions when com-
paring baseline and 1-month FU results. These results remained
stable until the 12-month FU for most of the variables measured,
with exception of the scar height measured by PRIMOSpico,
which revealed a minimal increase between 1- and 12-month
FU. The latter finding may be the consequence of a small per-
centage of patients who exhibit signs of minimal recurrence.
However, based on their POSAS evaluations, which showed
highly significant ameliorations for all variables of interest, all
patients and the observer noted significant improvements over
the entire study duration. Importantly, all patients demonstrated
great improvements in their quality of life as indicated by their
DLQI scores. The latter finding may be a compelling motivation
for more frequent consideration of this therapy in daily medical
practice, as keloids are known to have a significant impact on
affected patients’ quality of life.26
As with most clinical surveys in the field of scar therapy, our
study could not provide certain important information. Most
critically, we were unable to include a control group or a placebo
group, as the ethics committee did not permit patients to be left
untreated. In addition, a variety of studies have already demon-
strated that combinations of TAC and 5-FU may be superior to
the respective monotherapies.
In conclusion, the results of this study confirm the efficacy and
safety of the use of a combination of 5-FU and TAC in a 3 : 1 ratio
in keloids based on objective measurements. Treatments were well
tolerated and demonstrated stable results at 12-month FU.
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